» Articles » PMID: 32646847

Concurrence of HBV Infection and Non-alcoholic Fatty Liver Disease is Associated with Higher Prevalence of Chronic Kidney Disease

Overview
Specialty Gastroenterology
Date 2020 Jul 11
PMID 32646847
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: Coexistence of non-alcoholic fatty liver disease (NAFLD) and hepatitis B virus (HBV) infection is common in clinical practice. This study was to explore the prevalence of chronic kidney disease (CKD) in patients with NAFLD and/or HBV.

Methods: Participants who received health examination in a physical examination center were included in this cross-sectional study. Binary logistic regression was used to estimate the odds ratios (ORs) for CKD.

Results: A total of 32,578 cases were included in the final analysis, with 52.3% males and an average age of 44.01±13.09 years old. The positive rate of HBV surface antigen was 14.5% and NAFLD was diagnosed in 30.2% cases. The coexistence of NAFLD and HBV-infection was found in 1,275 (3.9%) cases. In overall population, 713 (2.2%) cases were diagnosed with CKD. The CKD prevalence were 1.4%, 2.1%, 3.5% and 5.0% in those without NAFLD or HBV, HBV-infection alone, NAFLD alone and those with concomitant HBV-infection and NAFLD, respectively. After adjustment for age, sex, body mass index, diabetes and hypertension, the correlation between CKD and liver disease was still significant in HBV group (OR=1.388, 95%CI: 1.055-1.809), yet no longer existed in patients with NAFLD (OR=1.183, 95%CI: 0.986-1.420). The concomitant of NAFLD and HBV infection was associated with a higher odds ratio for CKD compared to any other group (OR=1.961, 95%CI=1.454-2.645).

Conclusions: The coexistence of NAFLD and HBV increases the risk of CKD by 2-fold. The control of multiple liver diseases will be beneficial not only to liver but also to kidney.

Citing Articles

Characterizing Unique Clinical and Virological Profiles in Concurrent Chronic Hepatitis B and Metabolic Dysfunction-Associated Liver Disease: Insights from a Population-Based Cohort Study.

Abu Baker F, Zeina A, Taher R, Mouch S, Israel A J Clin Med. 2024; 13(18).

PMID: 39337094 PMC: 11433373. DOI: 10.3390/jcm13185608.


Severe Hepatic Steatosis Is Associated With Low-Level Viremia and Advanced Fibrosis in Patients With Chronic Hepatitis B in North America.

Ko H, Patel N, Haylock-Jacobs S, Doucette K, Ma M, Cooper C Gastro Hep Adv. 2024; 1(1):106-116.

PMID: 39129930 PMC: 11307651. DOI: 10.1016/j.gastha.2021.09.005.


Hepatitis B virus infection as a risk factor for chronic kidney disease: a systematic review and meta-analysis.

Chen D, Yu R, Yin S, Qiu W, Fang J, Peng X BMC Infect Dis. 2024; 24(1):620.

PMID: 38909191 PMC: 11193185. DOI: 10.1186/s12879-024-09546-z.


Increased risk of incident diabetes in patients with MAFLD not meeting the criteria for NAFLD.

Park S, Park J, Kwon S, Lee Y, Kim G, Hur K Sci Rep. 2023; 13(1):10677.

PMID: 37393407 PMC: 10314928. DOI: 10.1038/s41598-023-37858-8.


NAFLD and HBV interplay - related mechanisms underlying liver disease progression.

Tourkochristou E, Assimakopoulos S, Thomopoulos K, Marangos M, Triantos C Front Immunol. 2022; 13:965548.

PMID: 36544761 PMC: 9760931. DOI: 10.3389/fimmu.2022.965548.